DENOSUMAB

Course overview

DENOSUMAB IS A BONE ANTI-RESORPTIVE DRUG USED FOR THE TREATMENT OF OSTEOPOROSIS AND OTHER BONE-RELATED DISORDERS. FDA-APPROVED INDICATIONS INCLUDE PREVENTION OF SKELETAL-RELATED EVENTS (E.G., BONE PAIN AND FRACTURES) SECONDARY TO MULTIPLE MYELOMA OR BONE METASTASES FROM SOLID TUMORS, GIANT CELL TUMOR OF THE BONE, HYPERCALCEMIA OF MALIGNANCY, OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE AS WELL AS MEN WITH OSTEOPOROSIS AT HIGH RISK OF FRACTURE, GLUCOCORTICOID-INDUCED OSTEOPOROSIS, AND BONE LOSS. THIS ACTIVITY REVIEWS THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, TOXICITY, DOSING, PHARMACODYNAMICS, AND MONITORING OF DENOSUMAB PERTINENT FOR INTERPROFESSIONAL TEAM MEMBERS WHEN DENOSUMAB THERAPY IS APPROPRIATE TO ACHIEVE OPTIMAL PATIENT OUTCOMES.